Theravance Biopharma Revenue, Profits - TBPH Quarterly Income Statement

Add to My Stocks
$26.93 $0.52 (1.89%) TBPH stock closing price Sep 17, 2018 (Closing)

TBPH stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Theravance Biopharma stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. Like any other income statement, the TBPH income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue growth of 182.21% when compared to the same period in the past. One also needs to look at Theravance Biopharma assets, operating expenses and Theravance Biopharma free cash flow. The Theravance Biopharma profit and loss statement shows revenue of $23.48M for 2018 Q2. Revenue has grown by 182.21% QoQ for TBPH stock.

View and download details of revenue and profits for Theravance Biopharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Theravance Biopharma Revenues or Net Sales
Cost Of Goods Sold (COGS)-1.45M-3.13M-1.36M-1.16M---
Theravance Biopharma Gross Profit
Research & Development Expense48.62M47.76M51.06M39.34M42.92M40.56M42.03M31.95M32.06M35.67M
Selling General & Admin Expense25.01M24.7M29.54M20.94M24.33M20.78M20.37M20.28M20.26M23.59M
Income Before Depreciation Depletion Amortization-48.7M-64.97M-79.19M-56.99M-65.12M-58.82M-57.84M-33.49M-47.49M-41.64M
Depreciation Depletion Amortization----------
Non Operating Income3.23M2.17M1.38M-6.87M1.42M1.03M----
Interest Expense2.14M2.13M2.15M2.13M2.13M2.13M1.4M---
Theravance Biopharma Pretax Income
Provision for Income Taxes-6.79M-7M--5.38M8.58M---
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-40.82M-65.09M-86.99M-66.88M-66.29M-65.32M-67.33M-33.96M-47.23M-42.15M
Extraordinary Items & Discontinued Operations----------
Theravance Biopharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS53.8M53.26M52.91M52.61M52.26M51.62M49.57M46.47M44.41M38.33M
Average Shares used to compute Basic EPS53.8M53.26M52.91M52.61M52.26M51.62M49.57M46.47M44.41M38.33M
Income Before Nonrecurring Items-40.82M-65.09M-86.99M-66.88M-66.29M-65.32M-67.33M-33.96M-47.23M-42.15M
Income from Nonrecurring Items----------
Theravance Biopharma Earnings Per Share Basic Net
Theravance Biopharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.76-1.22-1.64-1.27-1.27-1.27-1.36-0.73-1.06-1.10
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Theravance Biopharma stock analysis are:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that TBPH stock has a topline or revenue of $23.48M for 2018 Q2 as per this Theravance Biopharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-40.82M for Theravance Biopharma for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the TBPH income statement, one can check the Theravance Biopharma historical stock prices to check how the price has moved with time.

Theravance Biopharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield

Other Income Statements - Theravance Biopharma Inc Industry Peers

Arrowhead Pharma income statement, Merck income statement, Pfizer income statement